ow dose estramustine phosphate against castration-resistant prostate cancer: phase II study
Phase 2
- Conditions
- Castration-resistant prostate cancer
- Registration Number
- JPRN-UMIN000004406
- Lead Sponsor
- Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have had estramustine phosphate therapy (including other estrogen-based hormone therapy) 2) Patients with malignancy within 5 years except carcinoma in situ or other malignancies limited within visceral mucosa 3) History of phlebitis, pulmonary embolism, intracranial infarction and coronary diseases 4) History of severe heart disease and renal diseases 5) Patients with active peptic ulcer 6) Psychiatric illness that makes it undesirable for the subject to participate in the trial 7) Evidence of any other significant disorder that make it undesirable for enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA response rate
- Secondary Outcome Measures
Name Time Method